Sei Investments Co. Increases Stake in CG Oncology, Inc. $CGON

Sei Investments Co. boosted its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 111.6% during the first quarter, Holdings Channel.com reports. The institutional investor owned 18,089 shares of the company’s stock after buying an additional 9,542 shares during the period. Sei Investments Co.’s holdings in CG Oncology were worth $1,225,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of CGON. AQR Capital Management LLC purchased a new position in CG Oncology in the first quarter valued at $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of CG Oncology by 18.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after buying an additional 5,442 shares during the period. Millennium Management LLC grew its position in shares of CG Oncology by 139.4% during the first quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after buying an additional 347,055 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of CG Oncology by 42.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after buying an additional 53,461 shares during the period. Finally, Legal & General Group Plc raised its holdings in CG Oncology by 12.3% in the second quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after acquiring an additional 4,847 shares in the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Insider Buying and Selling

In related news, Director Brian Guan-Chyun Liu bought 371,085 shares of the stock in a transaction on Thursday, June 25th. The shares were bought at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the purchase, the director owned 1,886,236 shares of the company’s stock, valued at $126,132,601.32. This trade represents a 24.49% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director James Mulay sold 24,165 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the sale, the director owned 24,165 shares of the company’s stock, valued at $1,816,241.40. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 37,129 shares of company stock valued at $2,663,817 over the last quarter. 4.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CGON has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Wall Street Zen downgraded CG Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday. Wedbush increased their price objective on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Finally, Royal Bank Of Canada decreased their target price on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and a consensus price target of $83.18.

CG Oncology Trading Up 0.6%

Shares of CGON opened at $77.03 on Wednesday. The company’s 50 day simple moving average is $67.90 and its 200-day simple moving average is $64.31. The firm has a market cap of $6.83 billion, a PE ratio of -28.64 and a beta of 0.23. CG Oncology, Inc. has a 12-month low of $24.10 and a 12-month high of $77.49.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative return on equity of 26.58% and a negative net margin of 3,602.68%. As a group, equities research analysts forecast that CG Oncology, Inc. will post -3.14 EPS for the current fiscal year.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.